Altimmune (ALT) announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, for the treatment of patients with metabolic dysfunction-associated steatohepatitis.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up
- Altimmune’s IMPACT NASH Trial Completion Puts Pemvidutide Back in the Spotlight
- Midday Fly By: Nike reports Q2 beat, TikTok to sell U.S. unit
- Altimmune sinks 21% to $3.98 after Phase 2b MASH data
- Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target